Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.

CATX | US

Overview

Corporate Details

ISIN(s):
US46489V1044 (+1 more)
LEI:
Country:
United States of America
Address:
2401 ELLIOTT AVENUE, 98121 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company pioneering advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its proprietary technology platform uses a revolutionary lead-212 (Pb-212) based approach, conjugating radioisotopes to high-affinity targeting peptides. This theranostic method allows physicians to first image tumors to confirm targets and then deliver potent, short-range alpha radiation directly to cancer cells, aiming to maximize efficacy while minimizing damage to surrounding healthy tissue. The company's clinical pipeline is focused on oncology, with programs targeting melanoma, neuroendocrine tumors, and other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Perspective Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perspective Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perspective Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM
Vera Therapeutics, Inc. Logo
Developing biologic therapies for serious immunological diseases, focusing on IgA Nephropathy.
United States of America
VERA
Vericel Corp Logo
Develops autologous cell therapies for sports medicine and severe burn care markets.
United States of America
VCEL
Verona Pharma plc Logo
Develops innovative therapies for chronic respiratory diseases like COPD and asthma.
United States of America
VRNA
Verrica Pharmaceuticals Inc. Logo
Develops topical therapies for skin diseases like molluscum contagiosum and common warts.
United States of America
VRCA
VERTEX PHARMACEUTICALS INC / MA Logo
Develops transformative medicines for serious diseases, specializing in cystic fibrosis.
United States of America
VRTX
VERU INC. Logo
Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.
United States of America
VERU
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France
VETO
Viatris Inc Logo
A global healthcare company distributing branded and generic medicines in over 165 countries.
United States of America
VTRS
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland
VIFN

Talk to a Data Expert

Have a question? We'll get back to you promptly.